Last update 28 Nov 2024
Recombinant humanized anti-VEGF monoclonal antibody(Teresi Pharmaceuticals)
Last update 28 Nov 2024
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms Bevacizumab biosimilar(Teresi Pharmaceuticals), TRS-003 |
Target |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 41632H
Source: *****
Sequence Code 41637L
Source: *****
Related
5
Clinical Trials associated with Recombinant humanized anti-VEGF monoclonal antibody(Teresi Pharmaceuticals)A Phase 3, Multicenter, Randomized and Double-blind Study Assessing the Interchangeability Between TRS003 and China-approved Bevacizumab® (Also Called China-approved Avastin) For First-Line Treatment of Patients With Metastatic Colorectal Cancer (CRC)
评估TRS003 与中国许可的贝伐珠单抗®分别联合紫杉醇-卡铂治疗晚期非鳞非小细胞肺癌（NSCLC）受试者的有效性及安全性一致性的多中心、随机、双盲、III 期研究
[Translation] A multicenter, randomized, double-blind, Phase III study to evaluate the efficacy and safety of TRS003 and China-licensed bevacizumab® in combination with paclitaxel-carboplatin in subjects with advanced non-squamous non-small cell lung cancer (NSCLC)
A Phase 3, Multicenter, Randomized and Double-Blind Study to Assess the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab in Subjects With Advanced Nonsquamous NSCLC
100 Clinical Results associated with Recombinant humanized anti-VEGF monoclonal antibody(Teresi Pharmaceuticals)
Login to view more data
100 Translational Medicine associated with Recombinant humanized anti-VEGF monoclonal antibody(Teresi Pharmaceuticals)
Login to view more data
100 Patents (Medical) associated with Recombinant humanized anti-VEGF monoclonal antibody(Teresi Pharmaceuticals)
Login to view more data
100 Deals associated with Recombinant humanized anti-VEGF monoclonal antibody(Teresi Pharmaceuticals)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Non-squamous non-small cell lung cancer | Phase 3 | CN | 17 Aug 2020 | |
| Glioblastoma | Phase 3 | CN | - | |
| Kidney Neoplasms | Phase 3 | CN | - | |
| Liver Cancer | Phase 3 | CN | - | |
| Metastatic Colorectal Carcinoma | Phase 3 | CN | - | |
| Ovarian Cancer | Phase 3 | CN | - | |
| Uterine Cervical Cancer | Phase 3 | CN | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | - | 114 | (TRS003) | owfjtexdxw(jkhjkdnhtj) = tfngeqpuqf yuxbgvujkj (voumpuxewe, skulpnkovg - liikdcnfwk) View more | - | 16 Jun 2020 | |
(China-approved Bevacizumab) | owfjtexdxw(jkhjkdnhtj) = tsahljrukt yuxbgvujkj (voumpuxewe, gdyaqlyqeo - ymvzdqtdjp) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free